<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480987</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1089</org_study_id>
    <nct_id>NCT00480987</nct_id>
  </id_info>
  <brief_title>Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration &lt; 1 Year</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of oxaliplatin&#xD;
      combined with fludarabine plus cytarabine that can be given to patients with Acute Myeloid&#xD;
      Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). Once the highest tolerable dose&#xD;
      of oxaliplatin in this drug combination is found, the next goal of the study will be to learn&#xD;
      the safety and the ability of the drug combination to control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Cytarabine is designed to insert itself into Deoxyribonucleic acid (DNA) (the genetic&#xD;
      material of cells) and stop the DNA from repairing itself.&#xD;
&#xD;
      Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may&#xD;
      increase the likelihood of the cells dying.&#xD;
&#xD;
      Oxaliplatin is designed to &quot;program&quot; cells to cause death in leukemic cells.&#xD;
&#xD;
      The Phases of The Study:&#xD;
&#xD;
      This research study has 2 parts, Phase I and Phase II.&#xD;
&#xD;
      The Phase I part of the study will be used to test different dose levels in order to&#xD;
      determine the highest tolerable dose of the study drug oxaliplatin that can be given in&#xD;
      combination with cytarabine and fludarabine to patients with AML or high-risk MDS. Three (3)&#xD;
      participants will be enrolled at each dose level until the highest tolerable dose is found.&#xD;
&#xD;
      The Phase II part of the study will evaluate the safety and disease-control ability of the&#xD;
      study drug combination (the highest tolerable dose that was found) in order to treat these&#xD;
      patients.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be given oxaliplatin&#xD;
      through a needle (intravenously -- through an IV) in your vein over 2 hours for 4 days (Days&#xD;
      1-4) in a row.&#xD;
&#xD;
      On Day 2, you will be given cytarabine through an IV in your vein by continuous infusion over&#xD;
      24 hours for 5 days (Days 2-6) in a row. Starting on Day 2, you will be given fludarabine&#xD;
      through an IV in your vein over 30 minutes for 5 days (Days 2-6) in a row. In order to keep&#xD;
      you from being dehydrated, you will also be given other IV fluids, such as saline (a salt&#xD;
      solution), each day you receive the study drugs. If the drugs are given on an outpatient&#xD;
      basis, a daily visit may take about 8 hours.&#xD;
&#xD;
      One (1) cycle is 6 days long. The first cycle will be given at M. D. Anderson. Each cycle&#xD;
      will be repeated every 4-6 weeks. Depending on your response to the study drug combination,&#xD;
      you will have up to 5 more cycles either at M. D. Anderson or on an outpatient basis with&#xD;
      your regular physician.&#xD;
&#xD;
      Your study drug dose may be lowered if you experience severe side effects.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      During each treatment cycle, you will have blood drawn (about 1 teaspoon each time) at least&#xD;
      2-3 times a week for routine tests. You will have a bone marrow aspiration done on Day 21 of&#xD;
      Cycle 1 and once a week thereafter, unless there is clear evidence of active disease. To&#xD;
      collect a bone marrow aspirate, an area of the hip or chest bone is numbed with anesthetic,&#xD;
      and a small amount of bone marrow is withdrawn through a large needle.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will remain on this study for up to 6 cycles for a total of about 6 months, unless the&#xD;
      disease is not responding, the disease gets worse, or you experience intolerable side&#xD;
      effects. If you are taken off this study early, your study doctor will discuss other&#xD;
      treatment options with you.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      Once you have completed treatment on this study, you will have an end-of-treatment visit.&#xD;
      This visit will include routine blood tests (about 1 teaspoon will be drawn each time) and a&#xD;
      bone marrow aspirate to check the status of the disease. If your blood tests show the disease&#xD;
      has gotten worse, no bone marrow aspirate will be needed.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      After your last cycle of treatment is completed and every 3 months for as long as you are in&#xD;
      remission, you will have blood drawn (about 2 teaspoons each) for routine testing.&#xD;
&#xD;
      This is an investigational study. Cytarabine is Food and Drug Administration (FDA) approved&#xD;
      and commercially available for the treatment of AML and other blood cancers. Fludarabine is&#xD;
      FDA approved and commercially available for the treatment of chronic lymphocytic leukemia&#xD;
      (CLL). Oxaliplatin is FDA approved and commercially available for the treatment of advanced&#xD;
      colorectal cancer and colon cancer. Their use in combination is investigational in this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of support.&#xD;
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Objective Response</measure>
    <time_frame>After 2 months</time_frame>
    <description>Objective response: Complete Response/Remission (CR) defined as a bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/Liters or more and platelet count of 100*10^9/Liters or more; Complete Response with Platelets/remission without platelet recovery (CRp) defined as a complete response except for a platelet less than 100*10^9/Liters and transfusion independent; and Partial Response/Remission defined as peripheral blood count recovery as for CR with decrease in marrow blasts &gt;/= 50% and not more than 6-25% abnormal cells in the marrow.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin + Cytarabine + Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>30 mg/m^2 IV days 1-4</description>
    <arm_group_label>Oxaliplatin + Cytarabine + Fludarabine</arm_group_label>
    <other_name>Eloxatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 IV days 2-6</description>
    <arm_group_label>Oxaliplatin + Cytarabine + Fludarabine</arm_group_label>
    <other_name>Fludara®</other_name>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>500 mg/m^2 by IV continuous infusion days 2-6</description>
    <arm_group_label>Oxaliplatin + Cytarabine + Fludarabine</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed relapsed or refractory acute myeloid&#xD;
             leukemia (AML) or high-risk myelodysplastic syndrome.&#xD;
&#xD;
          -  Performance status 0-2 (Zubrod scale).&#xD;
&#xD;
          -  Serum creatinine equal or less than 1.3 mg/dL or creatinine clearance &gt; 40 mL/min.&#xD;
&#xD;
          -  Bilirubin &lt;/= 2 mg/dL; serum glutamic oxaloacetic transaminase (SGOT) or Serum&#xD;
             glutamic pyruvic transaminase (SGPT) &lt;/= 3 times the Upper Limit of Normal (ULN) for&#xD;
             the reference lab unless due to leukemia or congenital hemolytic disorder (for&#xD;
             bilirubin).&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No untreated or uncontrolled life-threatening infection.&#xD;
&#xD;
          -  No oxaliplatin, fludarabine, or cytarabine intolerance.&#xD;
&#xD;
          -  No pregnancy or lactation. Female patients of childbearing potential (including those&#xD;
             &lt; 1 year post-menopausal) and male patients must agree to use contraception.&#xD;
&#xD;
          -  No chemotherapy or radiation therapy within 4 weeks of study entry. Hydroxyurea is&#xD;
             allowed prior to starting therapy in the setting of rapidly proliferating disease.&#xD;
&#xD;
          -  No other medical condition, including mental illness or substance abuse, deemed by the&#xD;
             Investigator to be likely to interfere with a patient's ability to sign informed&#xD;
             consent or cooperate and participate in the study or to interfere with the&#xD;
             interpretation of the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <results_first_submitted>June 6, 2011</results_first_submitted>
  <results_first_submitted_qc>June 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-Risk Myelodysplastic Syndromes</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 1/15/08 - 11/3/09; all patients were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>There were 27 participants registered and all were included in the analysis. The trial terminated early.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxaliplatin + Cytarabine + Fludarabine</title>
          <description>Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin + Cytarabine + Fludarabine</title>
          <description>Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="6" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Objective Response</title>
        <description>Objective response: Complete Response/Remission (CR) defined as a bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/Liters or more and platelet count of 100*10^9/Liters or more; Complete Response with Platelets/remission without platelet recovery (CRp) defined as a complete response except for a platelet less than 100*10^9/Liters and transfusion independent; and Partial Response/Remission defined as peripheral blood count recovery as for CR with decrease in marrow blasts &gt;/= 50% and not more than 6-25% abnormal cells in the marrow.</description>
        <time_frame>After 2 months</time_frame>
        <population>Analysis was per protocol. All participants treated were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin + Cytarabine + Fludarabine</title>
            <description>Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response</title>
          <description>Objective response: Complete Response/Remission (CR) defined as a bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/Liters or more and platelet count of 100*10^9/Liters or more; Complete Response with Platelets/remission without platelet recovery (CRp) defined as a complete response except for a platelet less than 100*10^9/Liters and transfusion independent; and Partial Response/Remission defined as peripheral blood count recovery as for CR with decrease in marrow blasts &gt;/= 50% and not more than 6-25% abnormal cells in the marrow.</description>
          <population>Analysis was per protocol. All participants treated were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete response with platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxaliplatin + Cytarabine + Fludarabine</title>
          <description>Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Disease Progression</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gautam Borthakur, MBBS / Assistant Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713-792-7305</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

